A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Prior treatment

• Participants who previously received anti-CD20 therapy at any time; any approved therapy to treat MS within 5 half-lives of the medication prior to screening.
  • Note: Other Inclusion/Exclusion criteria may apply.

Other illness

• Active chronic disease of the immune system other than MS or immunodeficiency syndrome.

Other

• Primary-progressive Multiple Sclerosis (PPMS) or inactive Secondary Progressive Multiple Sclerosis (SPMS).
• Participants with significantly impaired bone marrow function or significant leukopenia or thrombocytopenia.

• Diagnosis of RMS (2017 Revised McDonald criteria).
• Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
• Neurologically stable for \> 30 days prior to Screening and Day 1.
• Female participants of childbearing potential must consent to use a highly effective method of contraception from consent and for 6 months after the last dose of ublituximab.